Inter- and Intraobserver Variability on Endoscopic Scoring Systems in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis

被引:3
|
作者
Hashash, Jana G. [1 ]
Ng, Faye Yu Ci [2 ]
Farraye, Francis A. [1 ]
Wang, Yeli [2 ]
Colucci, Daniel R. [2 ]
Baxi, Shrujal [2 ]
Muneer, Sadaf [2 ]
Reddan, Mitchell [2 ]
Shingru, Pratik [2 ]
Melmed, Gil Y. [3 ,4 ]
机构
[1] Mayo Clin, Inflammatory Bowel Dis Ctr, Div Gastroenterol & Hepatol, Jacksonville, FL USA
[2] Iterat Hlth Inc, Cambridge, MA USA
[3] Cedars Sinai Med Ctr, Div Gastroenterol & Hepatol, Los Angeles, CA USA
[4] Cedars Sinai, Karsh Div Gastroenterol & Hepatol, 8730 Alden Dr,Thalians Bldg, Los Angeles, CA 90048 USA
关键词
endoscopy; Crohn's disease; ulcerative colitis; endoscopic scoring; interobserver variability; intraobserver variability; RELIABILITY; VALIDATION; AGREEMENT; SEVERITY; SCORES; INDEX;
D O I
10.1093/ibd/izae051
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Endoscopy scoring is a key component in the diagnosis of ulcerative colitis (UC) and Crohn's disease (CD). Variability in endoscopic scoring can impact patient trial eligibility and treatment effect measurement. In this study, we examine inter- and intraobserver variability of inflammatory bowel disease endoscopic scoring systems in a systematic review and meta-analysis.Methods We included observational studies that evaluated the inter- and intraobserver variability using UC (endoscopic Mayo Score [eMS], Ulcerative Colitis Endoscopic Index of Severity [UCEIS]) or CD (Crohn's Disease Endoscopic Index of Severity [CDEIS], Simple Endoscopic Score for Crohn's Disease [SES-CD]) systems among adults (>= 18 years of age) and were published in English. The strength of agreement was categorized as fair, moderate, good, and very good.Results A total of 6003 records were identified. After screening, 13 studies were included in our analysis. The overall interobserver agreement rates were 0.58 for eMS, 0.66 for UCEIS, 0.80 for CDEIS, and 0.78 for SES-CD. The overall heterogeneity (I2) for these systems ranged from 93.2% to 99.2%. A few studies assessed the intraobserver agreement rate. The overall effect sizes were 0.75 for eMS, 0.87 for UCEIS, 0.89 for CDEIS, and 0.91 for SES-CD.Conclusions The interobserver agreement rates for eMS, UCEIS, CDEIS, and SES-CD ranged from moderate to good. The intraobserver agreement rates for eMS, UCEIS, CDEIS, and SES-CD ranged from good to very good. Solutions to improve interobserver agreement could allow for more accurate patient assessment, leading to richer, more accurate clinical management and clinical trial data. This study examined the inter- and intraobserver variability of inflammatory bowel disease endoscopic scoring systems (endoscopic Mayo Score, Ulcerative Colitis Endoscopic Index of Severity, Crohn's Disease Endoscopic Index of Severity, Simple Endoscopic Score for Crohn's Disease) in a systematic review and meta-analysis.
引用
收藏
页码:2217 / 2226
页数:10
相关论文
共 50 条
  • [1] Inter- and Intra-Observer Variability of Endoscopic Scoring Systems in Ulcerative Colitis and Crohn's Disease: A Systematic Review and Meta-Analysis
    Hashash, Jana G.
    Farraye, Francis A.
    Wang, Yeli
    Colucci, Daniel
    Baxi, Shrujal
    Muneer, Sadaf
    Ng, Faye Yu Ci
    Shingru, Pratik
    Melmed, Gil
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S540 - S540
  • [2] Prevalence of Gallstones in Ulcerative Colitis and Crohn's Disease: A Systematic Review and Meta-Analysis
    Baig, Mirza M. A.
    Irfan, Shayan A.
    Sumbal, Anusha
    Sumbal, Ramish
    Kumar, Sanjay
    Ahmad, Junaid
    Gandrakota, Nikhila
    Qadar, Laila Tul
    Chaudhry, Maida S.
    Feroz, Azka
    Warraich, Muhammad Sheharyar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [3] Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis
    Xu, L.
    Lochhead, P.
    Ko, Y.
    Claggett, B.
    Leong, R. W.
    Ananthakrishnan, A. N.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (09) : 780 - 789
  • [4] Indirect health costs in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis
    Kawalec, Pawel
    Malinowski, Krzysztof Piotr
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (02) : 253 - 266
  • [5] Health utility of patients with Crohn's disease and ulcerative colitis: a systematic review and meta-analysis
    Malinowski, Krzysztof Piotr
    Kawalec, Pawel
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (04) : 441 - 453
  • [6] Assisted reproductive technology in women with Crohn's disease and ulcerative colitis: A systematic review and meta-analysis
    Laube, R.
    Tran, Y.
    Paramsothy, S.
    Leong, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 134 - 134
  • [7] Differences in the prevalence of uveitis between Crohn's disease and ulcerative colitis: A systematic review and meta-analysis
    Lin, Haowen
    Zhang, Jiaqing
    Liang, Chen
    Wu, Dongxuan
    Tan, Yuan
    Luo, Lixia
    Liu, Zhenzhen
    ACTA OPHTHALMOLOGICA, 2024, 102 (04) : e485 - e492
  • [8] Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis
    Attauabi, M.
    Madsen, G. R.
    Bendtsen, F.
    Seidelin, J. B.
    Burisch, J.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I483 - I484
  • [9] Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis
    Attauabi, Mohamed
    Madsen, Gorm Roager
    Bendtsen, Flemming
    Seidelin, Jakob Benedict
    Burisch, Johan
    DIGESTIVE AND LIVER DISEASE, 2022, 54 (09) : 1168 - 1178
  • [10] SYSTEMATIC REVIEW AND META-ANALYSIS OF MUCOSAL HEALING OUTCOMES WITH BIOLOGICS IN TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE
    Aggarwal, S.
    Kumar, S.
    Topaloglu, H.
    Bela, A.
    Topaloglu, O.
    VALUE IN HEALTH, 2022, 25 (12) : S41 - S41